The expensive part of building a healthcare startup is not always the software. It is the waiting: waiting for a hospital committee, waiting for a payer to bless a pilot, waiting for a security review, waiting for enough claims data to prove that the thing saves money. In consumer technology, distribution can arrive with a clever campaign. In healthcare, it often arrives through a person who trusts both the founder and the buyer. Flare Capital Partners has organized an investment firm around that bottleneck.
From its Boston office, Flare invests in the unglamorous machinery beneath modern care - clinical workflows, payer operations, workforce systems, data infrastructure and technology-enabled services. Its companies include ambient clinical intelligence provider Suki, utilization-management platform Cohere Health, real-world-data company HealthVerity and virtual specialty-care businesses such as Oshi Health. Patients may never see the plumbing. They notice when it fails.
The firm was founded in 2013 by Michael Greeley and Bill Geary, two investors with long histories in technology and healthcare. The timing was useful. The Affordable Care Act was pushing the system toward value-based models, smartphones had made virtual care plausible, and healthcare organizations were beginning to treat software as more than a back-office expense. Flare's thesis was narrow by venture standards: healthcare technology, early and often, with enough ownership to justify getting deeply involved.
The product after the check
Flare's core fund usually enters from seed through Series B. Its published range is $5 million to $30 million in total investment, with a target ownership stake of 10% to 20%. Those numbers reveal the job it wants: not tourist, not occasional board observer, but a concentrated early partner with time and reserves committed to the company-building process.
Money is only the first service. The firm helps recruit executives, shape go-to-market strategy, test product-market fit and navigate regulated sales. That sounds like familiar venture-platform language until the network underneath it comes into view. Flare's Industry Advisory Board includes senior figures from health systems, insurers, life-sciences companies and other healthcare organizations. The firms represented account for about $1.2 trillion in annual revenue, 68.5 million insured lives and roughly 15% of annual U.S. healthcare spending.
“Success requires more than capital - it takes deep understanding, the right connections, and a long-term mindset.”Flare Capital Partners
These executives are not decorative names on a slide. The proposition is that they can tell a startup why a product will stall in procurement, which outcome a buyer will pay to improve, and what evidence will move an experiment into a contract. Flare says its strategic partner network has contributed more than $1 billion in direct revenue to portfolio companies. That is a self-reported figure, but it is also the cleanest expression of the firm's differentiation: convert relationships into commercial motion.
A portfolio of pressure points
Flare does not sell a conventional product, and its portfolio does not fit into one product category. The organizing principle is friction. Cohere Health works on the administrative negotiation between health plans and providers. Suki reduces clinical documentation work. Axuall deals with the credentialing and workforce data that determine who is allowed to practice where. Aetion, acquired by Datavant, helps life-sciences companies, purchasers and regulators use real-world evidence. Each business attacks a seam where information, incentives or labor gets stuck.
Payer tech
Benefits, authorization, payments, risk and member navigation.
Clinical tech
Documentation, decisions, workforce intelligence and care coordination.
Infrastructure
Health data, security, evidence and the connective layer between systems.
Care delivery
Specialty, primary, behavioral and home-based models with measurable outcomes.
That makes the firm's ultimate customer set unusually broad. Limited partners buy exposure to the healthcare technology market. Founders receive capital and operating help. The portfolio companies, in turn, sell to plans, providers, employers, pharmaceutical companies, clinicians and sometimes patients. A single startup may need several of those groups to cooperate before its economics work. Sector expertise matters because the buyer, user, payer and beneficiary are often four different parties.
Flare also participates in company creation. It reports six proprietary co-creations, including businesses built with strategic partners. Inbound Health, for example, emerged with Allina Health to help other health systems deliver hospital and skilled-nursing care at home. Co-creation gives the startup a design partner and operating context at birth. It can also produce the classic corporate-venture tension: one institution's urgent problem is not automatically a national market. Flare's job is to distinguish a custom solution from a repeatable company.
The 509-person memory bank
The most quietly compounding part of the platform may be Flare Scholars. The program started in 2016 with 17 participants drawn from graduate programs and healthcare institutions. A decade later, the community contains 509 current and former scholars. Members receive mentorship, meet industry decision-makers, sit in on the mechanics of venture investing and can participate in Flare Scholar Ventures, the firm's pre-seed initiative.
A fellowship can look like corporate citizenship. Here it also behaves like infrastructure. Scholars become founders, operators, investors and healthcare executives. They bring ideas, recruit one another, recommend companies and carry Flare's network into institutions the firm may want to understand years later. The economics are not visible in a fund document, but the loop is easy to steal: teach talented people before you need something from them, give them a real community, then let time improve the network.
The useful lessonA vertical investor can compete with a larger generalist by owning the map: who buys, who regulates, who hires, which metric matters and where a young company is likely to get trapped.
AI meets the adoption problem
Healthcare's current AI cycle makes Flare's network argument more urgent. A compelling demo is easier to build than a safe deployment. Models touch sensitive data, sit inside clinical workflows and can create new failure modes when they scale. A hospital wants proof of accuracy and integration. A payer wants a measurable economic result. A founder needs to know whether the buyer's budget belongs to IT, clinical operations or a business line.
Flare launched an AI Advisory Council in 2025 to bring those conversations closer to the investment process. Its members include leaders from health systems, payers, pharmaceutical companies and technology organizations. The founding group drew executives from AdventHealth, Amazon Web Services, Amgen, Cincinnati Children's, CVS Health, GuideWell, Hartford HealthCare, MedStar Health, Memorial Hermann and Microsoft. A launch session at NVIDIA's headquarters focused on deployment bottlenecks rather than speculative futurism.
The council's stated offer is practical: structured product feedback, comparisons across markets, faster routes to pilots and early visibility into what buyers are actually adopting. That is useful to companies such as SmarterDx, Cohere Health, Suki, Layer Health and Axuall, where AI must survive contact with messy records, regulated decisions and overworked staff. Flare's view is that healthcare AI winners will be separated by distribution and integration, not by model cleverness alone.
Where Flare fits
The competitive set is crowded. Define Ventures, 7wireVentures, Town Hall Ventures, HealthQuest Capital and Oak HC/FT all bring healthcare specialization. General Catalyst, Andreessen Horowitz and GV bring larger brands, wider networks and deep pools of capital. Flare's answer is not to cover more territory. It is to stay close to early-stage healthcare technology and make the network denser.
Its fund history reflects a controlled expansion: $200 million in 2015, $255 million in 2019 and $350 million in 2022. The three disclosed core funds total $805 million, while the firm now describes the broader platform as nearly $1 billion in assets under management. The third fund was oversubscribed. That gives Flare enough scale to follow companies without turning every decision into a search for billion-dollar checks.
The approach still carries venture risk. Healthcare sales cycles remain slow. Regulation can redraw markets. Promising care models can discover that clinical quality and venture margins are uncomfortable roommates. The firm's 22 reported exits show liquidity, but not every outcome is public and a portfolio count is not a return multiple. Specialist knowledge does not repeal the power law.
What it can do is reduce avoidable mistakes. A founder can learn before launch that a savings claim will not pass a plan's actuarial test, that a workflow creates more clicks than it removes, or that a hospital's innovation budget cannot support a systemwide contract. In healthcare, those corrections may be worth more than a warm introduction. They compress a year of polite rejection into a month of useful disagreement.
Flare Capital's most persuasive idea is therefore modest: capital becomes more valuable when it arrives with context. The firm is building that context from advisers, customers, clinicians, technologists and hundreds of scholars. Plenty of investors can fund a healthcare company's runway. Flare is betting that the harder asset is a route through the system.